Clinical reagents that activate CD40 have been developed for systemic use and have shown clinical promise [6]–[8], but these agents do not necessarily drive T cell responses in vivo owing to restrictive features of the tumor microenvironment [8]. Here, CD40 is linked to neoplasm.